PureVax FeLV Vaccine for Protection of Cats against Feline Leukemia Virus Composition Purevax FeLV vaccine is made from a culture suspension of fibroblast cells from chicken SPF embryos infected with recombinant canarypox virus (vCP97) expressing FeLV genes, with the addition of water for injection up to 1 ml. Dosage form: suspension for injection. The vaccine is packaged in glass vials of 1 ml (1 dose). Vials with the vaccine are packed in boxes of 10 doses. Each box contains instructions for use of the vaccine. Qualitative and quantitative composition One dose of the vaccine (1 ml) contains: Active ingredient: FeLV recombinant canarypox virus, strain vCP97 - ≥ 107.2 KKID50; The filler is added to form 1 dose. Immunobiological properties The vaccine stimulates active immunity against feline leukemia; The period of immunity onset: 2 weeks after vaccination; Duration of immunity: for 1 year after the last vaccination. Application It is intended for the prevention of feline viral leukemia. The vaccine is intended for immunization of cats against leukemia, for the prevention of persistent viremia and for the reduction of clinical signs of the disease. Purevax FeLV is administered subcutaneously to kittens from 8 weeks of age. Contraindications Do not vaccinate females during pregnancy and lactation. Side effects After vaccination, a slight seal (<2 cm) may form at the injection site, which disappears within 1-4 weeks. Temporary apathy and hyperthermia may occur, lasting from 1 to 2 days. In exceptional cases, vaccination may cause a hypersensitivity reaction. In this case, symptomatic treatment is necessary. Special precautions for use Only clinically healthy animals are vaccinated. Aseptic rules must be observed during vaccination. During vaccination, use only sterile materials and equipment that do not contain disinfectants and antiseptics. Before vaccination, it is recommended to undergo a FeLV antigenemia test. Vaccination of FeLV-positive animals does not bring any benefit. Use during pregnancy and lactation Do not vaccinate females during pregnancy and lactation. Interaction with other products and other forms of interaction It is possible to use the Purevax VLK vaccine simultaneously with various combinations of components of Boehringer Ingelheim vaccines without adjuvant against viral rhinotracheitis, calicivirus, panleukopenia and chlamydia in cats and/or on the same day, but separately from the Boehringer Ingelheim vaccine against rabies or with various combinations of components of Boehringer Ingelheim vaccines against viral rhinotracheitis, calicivirus, panleukopenia and chlamydia in cats. Dosage and administration routes for animals of different ages The vaccine is administered subcutaneously, in one dose (1 ml), in accordance with the following vaccination schedule: Primary vaccination: one dose of the vaccine is used starting from the age of 8 weeks; one dose of the vaccine is used 3-4 weeks after the first administration. Revaccination: Revaccination is performed annually. For comprehensive protection of cats, the following vaccination schedule is recommended: 8 weeks: Purevax FeLV + Purevax RCP or Purevax RCPСh; 12 weeks: Purevax FeLV + Purevax RCP or Purevax RCPСh + Rabizin*; 15 months and then annually: Purevax FeLV + Purevax RCP or Purevax RCPСh. *Purevax and Rabizin vaccines are allowed to be used simultaneously, provided that they are administered separately. Overdose (symptoms, emergency measures, antidotes) Overdose may cause temporary apathy and hyperthermia lasting from 1 to 2 days. Special precautions None. Withdrawal period None. Special precautions for persons and service personnel administering protective equipment to animals General rules of asepsis and antisepsis must be followed during vaccination. In case of accidental injection to a person, seek medical attention immediately. Pharmaceutical features Main forms of incompatibility Do not mix with other medicinal products, except for those listed in the section "Interaction with other products and other forms of interaction". Advantages and features Powerful immune response without adjuvant due to innovative Canarypox FeLV technology. Efficiency of a modified live vaccine. Use of a viral vector with induction of both cellular and humoral immunity. Optimized safety profile with adjuvant-free protection. Non-replicative vector disappears after stimulation of immunity against FeLV. Shelf life 24 months. Shelf life after first opening: Use immediately. Special storage precautions Store and transport at a temperature of 2 ºC to 8 ºC in a place protected from light. Nature and composition of the primary packaging container Nature of the primary packaging of the vaccine: Type 1 glass vial containing 1 ml of vaccine. Plastic packaging contains 10, 20 or 50 glass vials of vaccine